Literature DB >> 22956241

Recurrence of IgG4-related disease following treatment with rituximab.

Jun Murakami1, Shoko Matsui, Shin Ishizawa, Kotaro Arita, Akinori Wada, Takayoshi Miyazono, Hiroyuki Hounoki, Koichiro Shinoda, Hirofumi Taki, Toshiro Sugiyama.   

Abstract

A 54-year-old woman with suspected low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type of the eyelids underwent rituximab-containing chemotherapy. She initially responded to the rituximab therapy, but later experienced two recurrences over a 3-year period. Biopsy specimens and a review of her previous histology revealed that she had had immunoglobulin G4-related disease at the initial presentation. Although IgG4-related disease seems to respond well to rituximab therapy, long-term follow up, including disease monitoring, is needed to evaluate disease remission.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22956241     DOI: 10.1007/s10165-012-0738-2

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  5 in total

Review 1.  Mechanisms and assessment of IgG4-related disease: lessons for the rheumatologist.

Authors:  Motohisa Yamamoto; Hiroki Takahashi; Yasuhisa Shinomura
Journal:  Nat Rev Rheumatol       Date:  2013-12-03       Impact factor: 20.543

2.  Rituximab for the treatment of IgG4-related orbital disease: experience from five cases.

Authors:  A Wu; N H Andrew; A Tsirbas; P Tan; A Gajdatsy; D Selva
Journal:  Eye (Lond)       Date:  2014-10-24       Impact factor: 3.775

3.  IgG4- related disease: an orphan disease with many faces.

Authors:  Herwig Pieringer; Ilse Parzer; Adelheid Wöhrer; Petra Reis; Bastian Oppl; Jochen Zwerina
Journal:  Orphanet J Rare Dis       Date:  2014-07-16       Impact factor: 4.123

Review 4.  IgG4-related disease: current challenges and future prospects.

Authors:  David Lang; Jochen Zwerina; Herwig Pieringer
Journal:  Ther Clin Risk Manag       Date:  2016-02-15       Impact factor: 2.423

5.  A case of proteinase 3 anti-neutrophil cytoplasmic antibody (PR3-ANCA) positive/IgG4-related lung disease.

Authors:  Hirokazu Touge; Katsuyuki Tomita; Akira Yamasaki; Eiji Shimizu
Journal:  Respir Med Case Rep       Date:  2017-01-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.